Therapeutics and Clinical Risk Management (Jul 2021)
High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
Abstract
Veysel Haksoyler,1 Erkan Topkan2 1Medline Hospital, Department of Medical Oncology, Adana, Turkey; 2Baskent University Medical Faculty, Department of Radiation Oncology, Adana, TurkeyCorrespondence: Erkan TopkanBaskent University Medical Faculty, Department of Radiation Oncology, Adana, 01120, TurkeyTel +90-533-7381069Fax +90-322-3444452Email [email protected]: In a lack of similar research, we assessed the prognostic utility of pretreatment platelet-to-albumin ratio (PAR) in locally advanced nasopharyngeal carcinoma (LANPC) patients managed with concurrent chemoradiotherapy (CCRT).Patients and Methods: Present retrospective analysis included a sum of 128 consecutively treated LANPC patients who underwent cisplatinum-based radical CCRT. Availability of an ideal pretreatment PAR cutoff that may stratify the study population into two cohorts with significantly distinct survival outcomes was sought by utilizing the receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively.Results: A rounded 5.2 [area under the curve (AUC): 68.9%; sensitivity: 67.4%; and specificity: 65.2%] value was identified as the ideal PAR cutoff that grouped patients into two gatherings [PAR≥ 5.2 (N=60) versus 5% at past six months (≤ 5%; P< 0.05 for PFS and OS, respectively).Conclusion: The results of the current retrospective analysis provided a robust and independent adverse prognostic value for pretreatment PAR ≥ 5.2 in terms of median and long-term PFS and OS outcomes in LA-NPC patients this patient group treated with conclusive CCRT.Keywords: concurrent chemoradiotherapy nasopharyngeal cancer, platelet-to-albumin ratio, prognostic worth, survival results
